HK Movers | TransThera Sciences Stock Soars 60% After Receiving Chinese Regulatory Nod for Cancer Drug Human Trial

MT Newswires Live

Sep 12

Shares of TransThera Sciences gained nearly 60% on Friday after a 21% rally in prior trading session.

The biopharmaceutical company said it received Chinese regulatory approval to begin a phase 2 human clinical trial of its core product tinengotinib in a type of breast cancer, according to a Hong Kong bourse filing Wednesday.

The company plans to study the drug in combination with fulvestrant as a treatment for HR+/HER2- relapsed or metastatic breast cancer.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/news/2566195840"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2566195840\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/2566195840?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-09-12 11:58","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2566195840","market":"sg","top_or_hot":-1,"title":"HK Movers | TransThera Sciences Stock Soars 60% After Receiving Chinese Regulatory Nod for Cancer Drug Human Trial","media":"MT Newswires Live","content":"<html><head></head><body><p>Shares of <a href=\"https://laohu8.com/S/02617\">TransThera Sciences</a> gained nearly 60% on Friday after a 21% rally in prior trading session.</p><p>The biopharmaceutical company said it received Chinese regulatory approval to begin a phase 2 human clinical trial of its core product tinengotinib in a type of breast cancer, according to a Hong Kong bourse filing Wednesday.</p><p class=\"t-img-caption\"><img src=\"https://community-static.tradeup.com/news/6cb2d2843657256488b660131f75e797\" tg-width=\"948\" tg-height=\"623\"/></p><p>The company plans to study the drug in combination with fulvestrant as a treatment for HR+/HER2- relapsed or metastatic breast cancer.</p></body></html>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>HK Movers | TransThera Sciences Stock Soars 60% After Receiving Chinese Regulatory Nod for Cancer Drug Human Trial</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nHK Movers | TransThera Sciences Stock Soars 60% After Receiving Chinese Regulatory Nod for Cancer Drug Human Trial\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1092851196\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/3002d84abbd5ace3c99397c7f95b8d4e);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">MT Newswires Live </p>\n<p class=\"h-time\">2025-09-12 11:58</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html><head></head><body><p>Shares of <a href=\"https://laohu8.com/S/02617\">TransThera Sciences</a> gained nearly 60% on Friday after a 21% rally in prior trading session.</p><p>The biopharmaceutical company said it received Chinese regulatory approval to begin a phase 2 human clinical trial of its core product tinengotinib in a type of breast cancer, according to a Hong Kong bourse filing Wednesday.</p><p class=\"t-img-caption\"><img src=\"https://community-static.tradeup.com/news/6cb2d2843657256488b660131f75e797\" tg-width=\"948\" tg-height=\"623\"/></p><p>The company plans to study the drug in combination with fulvestrant as a treatment for HR+/HER2- relapsed or metastatic breast cancer.</p></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK1161","symbol_name":"生物科技","start_time":0,"source_url":"https://www.mtnewswires.com/","article_id":"2566195840","we_media_id":"1092851196","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2566195840","pubTimestamp":1757649519,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"MT Newswires Live","introduction":"The most recognized names in North America, Europe and Asia rely on MT Newswires to power their applications. Better news, better service, better price.","home_visible":1,"id":"1092851196","head_image":"https://community-static.tradeup.com/news/3002d84abbd5ace3c99397c7f95b8d4e"},"summary":"Shares of $TransThera Sciences(02617)$ gained nearly 60% on Friday after a 21% rally in prior trading session.The biopharmaceutical company said it received Chinese regulatory approval to begin a...","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"BK1161":"生物科技","02617":"药捷安康-B"},"translate_title":"TransThera Sciences癌症药物人体试验获得中国监管机构批准","themeId":"db988090d391dada63985a8a8b176c17","isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"02617":0.9},"content_text":"Shares of TransThera Sciences gained nearly 60% on Friday after a 21% rally in prior trading session.The biopharmaceutical company said it received Chinese regulatory approval to begin a phase 2 human clinical trial of its core product tinengotinib in a type of breast cancer, according to a Hong Kong bourse filing Wednesday.The company plans to study the drug in combination with fulvestrant as a treatment for HR+/HER2- relapsed or metastatic breast cancer.","kind":"highlight","is_publish_news":true,"is_publish_highlight":true,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"2","news_tag":"productRelease,policyRegulatory","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"}}}